Revolution Medicines (RVMD) Operating Leases (2020 - 2026)

Revolution Medicines has reported Operating Leases for 7 years, with the latest figure at $140.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 15.37% year-over-year to $140.0 million; the trailing twelve-month figure through Mar 2026 stood at $140.0 million (up 15.37% YoY), and the FY2025 full-year result was $142.2 million, up 15.66% from the prior year.
• Operating Leases for Q1 2026 stood at $140.0 million, down from $142.2 million in the prior quarter.
• The five-year high for Operating Leases was $142.2 million in Q4 2025, with the low at $57.1 million in Q3 2023.
• Average Operating Leases over 5 years is $89.0 million, with a median of $79.1 million recorded in 2024.
• Peak annual rise in Operating Leases reached 116.88% in 2022, while the deepest fall reached 4.94% in 2022.
• Tracing RVMD's Operating Leases over 5 years: stood at $57.4 million in 2022, then soared by 40.3% to $80.6 million in 2023, then soared by 52.62% to $123.0 million in 2024, then increased by 15.66% to $142.2 million in 2025, then slipped by 1.56% to $140.0 million in 2026.
• The last three Operating Leases figures came in at $140.0 million (Q1 2026), $142.2 million (Q4 2025), and $142.1 million (Q3 2025), per Business Quant data.

Peer Comparison